

Resource Summary Report

Generated by [dkNET](#) on Sep 19, 2026

Brilliant Violet 605(TM) anti-mouse/human CD11b

RRID:AB_2565431

Type: Antibody

Proper Citation

BioLegend Cat# 101257, RRID:AB_2565431

Antibody Information

URL: http://antibodyregistry.org/AB_2565431

Proper Citation: BioLegend Cat# 101257, RRID:AB_2565431

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_2565431

Vendor: BioLegend

Catalog Number: 101257

Alternative Catalog Numbers: 101237

Record Creation Time: 20231110T035201+0000

Record Last Update: 20260830T022256+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-mouse/human CD11b.

No alerts have been found for Brilliant Violet 605(TM) anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 77 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Diamond EL, et al. (2026) RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. Cancer cell, 44(1), 203.

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. Cancer immunology research, 14(5), 718.

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. iScience, 29(6), 115978.

Skytthe M, et al. (2026) CD163 Expression Protects Against Early Hepatic Steatosis in Western Diet-Fed Male Mice. Gastro hep advances, 5(1), 100809.

Voisin T, et al. (2026) Skin inflammation and itch response are independently regulated by distinct nociceptor subsets. Immunity, 59(5), 1237.

Xu S, et al. (2026) Engineered MSCs enable bone marrow-targeted immunomodulation. Cell stem cell, 33(4), 660.

Bolli E, et al. (2026) CCL3 is produced by aged neutrophils across cancers and promotes tumor growth. Cancer cell, 44(3), 624.

Tang M, et al. (2026) TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy. Cell reports. Medicine, 7(7), 102876.

Kim JS, et al. (2025) Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging mice. Cell reports, 44(5), 115609.

Mirji G, et al. (2025) Aromatic microbial metabolite hippuric acid enhances inflammatory responses in macrophages via TLR-MyD88 signaling and lipid remodeling. Cell reports, 45(1), 116749.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. Immunity, 58(7), 1670.

Lamorte S, et al. (2025) Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. *Cancer cell*, 43(5), 955.

Lanzar ZR, et al. (2025) De-coupling immune parameters and toxicity associated with IL-12 agonism. *Cell reports*, 44(6), 115840.

Lucotti S, et al. (2025) Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. *Cell*, 188(6), 1642.

Keating N, et al. (2025) ARAP2 regulates responses to interferon-gamma by restricting SOCS1. *Cell reports*, 44(12), 116667.

Mayerhofer C, et al. (2025) OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis. *Cell metabolism*.

Tursi NJ, et al. (2025) Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity. *Cell reports. Medicine*, 6(4), 102035.

Reyes EY, et al. (2025) *Cryptococcus* exploits delayed microglial activation, and microglial osteopontin/Spp1 impairs peripheral host control. *Cell host & microbe*, 33(12), 2067.

Wienke J, et al. (2024) Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. *Cancer cell*, 42(2), 283.

Jia D, et al. (2024) Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. *Cell*, 187(7), 1651.